Patents by Inventor Catalin S. Buhimschi
Catalin S. Buhimschi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220043001Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions (e.g., kits) for the identification of subjects with misfolded proteins in their urine. For example, methods and compositions for determining that a urine sample from a pregnant woman contains or does not contain misfolded are provided. In some embodiments, the presence of misfolded proteins in a urine sample from a pregnant woman is an indication of preeclampsia.Type: ApplicationFiled: June 29, 2021Publication date: February 10, 2022Applicant: Yale UniversityInventors: Irina Buhimschi, Catalin S. Buhimschi, Michael Choma, Hemant Tagare, Stephan Michael Jonas
-
Patent number: 11125758Abstract: Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.Type: GrantFiled: August 17, 2017Date of Patent: September 21, 2021Assignees: Yale University, The Regents of the University of CaliforniaInventors: Catalin S. Buhimschi, Irina Buhimschi, Charles G. Glabe
-
Publication number: 20210255192Abstract: Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.Type: ApplicationFiled: March 2, 2021Publication date: August 19, 2021Applicant: Yale UniversityInventors: Catalin S. Buhimschi, Irina Buhimschi
-
Patent number: 11079392Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions (e.g., kits) for the identification of subjects with misfolded proteins in their urine. For example, methods and compositions for determining that a urine sample from a pregnant woman contains or does not contain misfolded are provided. In some embodiments, the presence of misfolded proteins in a urine sample from a pregnant woman is an indication of preeclampsia.Type: GrantFiled: May 8, 2019Date of Patent: August 3, 2021Assignee: Yale UniversityInventors: Irina Buhimschi, Catalin S. Buhimschi, Michael Choma, Hemant Tagare, Stephan Michael Jonas
-
Publication number: 20190353662Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions (e.g., kits) for the identification of subjects with misfolded proteins in their urine. For example, methods and compositions for determining that a urine sample from a pregnant woman contains or does not contain misfolded are provided. In some embodiments, the presence of misfolded proteins in a urine sample from a pregnant woman is an indication of preeclampsia.Type: ApplicationFiled: May 8, 2019Publication date: November 21, 2019Applicant: Yale UniversityInventors: Irina Buhimschi, Catalin S. Buhimschi, Michael Choma, Hemant Tagare, Stephan Michael Jonas
-
Patent number: 10324094Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions (e.g., kits) for the identification of subjects with misfolded proteins in their urine. For example, methods and compositions for determining that a urine sample from a pregnant woman contains or does not contain misfolded are provided. In some embodiments, the presence of misfolded proteins in a urine sample from a pregnant woman is an indication of preeclampsia.Type: GrantFiled: April 10, 2015Date of Patent: June 18, 2019Assignee: Yale UniversityInventors: Irina Buhimschi, Catalin S. Buhimschi, Michael Choma, Hemant Tagare, Stephan Michael Jonas
-
Patent number: 10048276Abstract: Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.Type: GrantFiled: September 10, 2015Date of Patent: August 14, 2018Assignee: Yale UniversityInventors: Catalin S. Buhimschi, Irina Buhimschi
-
Publication number: 20170356920Abstract: Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.Type: ApplicationFiled: August 17, 2017Publication date: December 14, 2017Applicant: Yale UniversityInventors: Catalin S. Buhimschi, Irina Buhimschi
-
Publication number: 20160097775Abstract: Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.Type: ApplicationFiled: September 10, 2015Publication date: April 7, 2016Applicants: Yale University, The Regents of the University of CaliforniaInventors: Catalin S. Buhimschi, Irina Buhimschi, Charles G. Glabe
-
Patent number: 9229009Abstract: Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.Type: GrantFiled: November 2, 2009Date of Patent: January 5, 2016Assignees: Yale University, The Regents of the University of CaliforniaInventors: Catalin S. Buhimschi, Irina Buhimschi, Charles G. Glabe
-
Publication number: 20150293115Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions (e.g., kits) for the identification of subjects with misfolded proteins in their urine. For example, methods and compositions for determining that a urine sample from a pregnant woman contains or does not contain misfolded are provided. In some embodiments, the presence of misfolded proteins in a urine sample from a pregnant woman is an indication of preeclampsia.Type: ApplicationFiled: April 10, 2015Publication date: October 15, 2015Applicant: YALE UNIVERSITYInventors: IRINA BUHIMSCHI, CATALIN S. BUHIMSCHI, MICHAEL CHOMA, HEMANT TAGARE, STEPHAN MICHAEL JONAS
-
Patent number: 8871448Abstract: The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.Type: GrantFiled: March 21, 2011Date of Patent: October 28, 2014Assignee: Yale UniversityInventors: Catalin S. Buhimschi, Irina Buhimschi, Errol Norwitz
-
Patent number: 8697367Abstract: Described herein are biomarkers, such as protein biomarkers, which are diagnostic of and predictive for complications that result from an in utero encounter, such as an infection by the fetus, that can lead to premature birth (PTB). The biomarkers can be used to identify fetuses and newborns at risk for complications of PTB, such as (Early Onset Neonatal Sepsis) EONS, intra-ventricular hemorrhage (IVH) and other poor outcomes.Type: GrantFiled: July 28, 2011Date of Patent: April 15, 2014Assignee: Yale UniversityInventors: Catalin S. Buhimschi, Irina Buhimschi, Vineet Bhandari
-
Patent number: 8263342Abstract: The invention relates, in part, to methods of using proteomic biomarkers to diagnose preeclampsia. In some aspects the invention, in part, relates to the detection of serpina-1 polypeptide and/or albumin polypeptide in samples from pregnant subjects. Samples from subjects may be compared to control samples to diagnose preeclampsia and/or to determine the onset, progression, or regression of preeclampsia in a subject. The invention also relates, in part, to screening methods to identify agents that can be used to treat preeclampsia and to determine the efficacy of a preeclampsia treatment. The invention, in part, also includes kits that are useful to diagnose and assess preeclampsia in a subject.Type: GrantFiled: October 27, 2006Date of Patent: September 11, 2012Assignee: Yale UniversityInventors: Catalin S. Buhimschi, Irina Buhimschi
-
Publication number: 20120040371Abstract: The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.Type: ApplicationFiled: March 21, 2011Publication date: February 16, 2012Applicant: Yale UniversityInventors: Catalin S. Buhimschi, Irina Buhimschi, Errol Norwitz
-
Publication number: 20120021442Abstract: Described herein are biomarkers, such as protein biomarkers, which are diagnostic of and predictive for complications that result from an in utero encounter, such as an infection by the fetus, that can lead to premature birth (PTB). The biomarkers can be used to identify fetuses and newborns at risk for complications of PTB, such as (Early Onset Neonatal Sepsis) EONS, intra-ventricular hemorrhage (IVH) and other poor outcomes.Type: ApplicationFiled: July 28, 2011Publication date: January 26, 2012Applicant: Yale UniversityInventors: Catalin S. Buhimschi, Irina Buhimschi, Vineet Bhandari
-
Publication number: 20110280863Abstract: Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.Type: ApplicationFiled: November 2, 2009Publication date: November 17, 2011Applicants: Regents of the University of California, The, Yale UniversityInventors: Catalin S. Buhimschi, Irina Buhimschi, Charles G. Glabe
-
Patent number: 7935496Abstract: The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.Type: GrantFiled: May 17, 2010Date of Patent: May 3, 2011Assignee: Yale UniversityInventors: Catalin S. Buhimschi, Irina Buhimschi, Errol Norwitz
-
Publication number: 20100227342Abstract: The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.Type: ApplicationFiled: May 17, 2010Publication date: September 9, 2010Applicant: Yale UniversityInventors: Catalin S. Buhimschi, Irina Buhimschi, Errol Norwitz
-
Patent number: 7727733Abstract: The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.Type: GrantFiled: December 21, 2005Date of Patent: June 1, 2010Assignee: Yale UniversityInventors: Catalin S. Buhimschi, Irina Buhimschi, Errol Norwitz